Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Forget Gilead, These 2 Pharma Dividends Pay Up To 10%

By Contrarian Outlook (Michael Foster)Stock MarketsMay 04, 2020 05:37AM ET
www.investing.com/analysis/forget-gilead-these-2-pharma-dividends-pay-up-to-10-200523484
Forget Gilead, These 2 Pharma Dividends Pay Up To 10%
By Contrarian Outlook (Michael Foster)   |  May 04, 2020 05:37AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

If you’re like pretty well everyone else, you’re closely watching Gilead Sciences (NASDAQ:GILD), creator of remdesivir, a drug that, last week, showed progress in treating the coronavirus in a US government study.

But does that make Gilead a good stock to buy now, particularly if you’re focused on income? Let’s take a look.

First up, unlike many other stocks these days, Gilead boasts a safe payout, with the dividend accounting for just 38% of free cash flow in the last 12 months. And the company has increased its dividend every year since initiating it in 2015:

A Reliable Dividend

GILEAD Dividend History
GILEAD Dividend History

It’s on the current-yield front where the dividend story starts to fray. I’ll say right now that Gilead has never been in league with my favorite investments—closed-end funds (CEFs) paying 7% or more. But buying it in late March would have gotten you a respectable 4% yield, the highest in the company’s history.

Gilead’s Dividend Peak Arrives—and Departs

GILEAD Dividend Yield
GILEAD Dividend Yield

But buying today, just over a month later, gets you a much smaller 3.1% yield. That, of course, is because the current yield falls as share prices rise, and Gilead’s stock has been on a remdesivir-fueled tear:

Coronavirus Treatment Progress Looks Priced In

GILEAD-SPY Total Return
GILEAD-SPY Total Return

With Gilead shares up over 30% year to date and near their 52-week high, optimism for the drug is already priced into the stock. And bear in mind, too, that an earlier Chinese study showed no improvement among patients treated with remdesivir versus those given a placebo (though that trial was much smaller than last week’s study, and patients were given the drug up to 12 days after showing symptoms, possibly too late for it to be effective).

As I said, the science is still out on this one, but the stock’s run means that any more negative news on remdesivir could send it plunging.

“Farm Out” Your Pharma Investments to the Pros

I mention Gilead not because it’s the stock of the moment, but because it’s a good segue into my favorite way to invest in pharma, a sector that should have some representation in your portfolio, for reasons that go beyond our current crisis. With the aging population, these companies’ treatments are going to be in high demand in the future.

But, of course, we’re not medical experts here at Contrarian Outlook, which is why I prefer to “hire” a team of pros to do my pharma stock-picking for me.

That would be the team at Tekla Capital Management. The Boston-based firm’s CEO, Dr. Daniel R. Omstead, is a Columbia Ph.D. in chemical engineering and applied chemistry who works with a group of Ivy League–trained biopharma experts to dig into which companies are producing drugs that work, and which are not. (I’m not affiliated with Tekla, nor have I received any financial compensation from them; I write this as an admirer of their work alone.)

As a result of this expertise, Tekla has managed funds that have crushed the pharma benchmark iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)) for years. And right now, two of Tekla’s funds are worth considering: the Tekla World Healthcare Fund (NYSE:THW) and the Tekla Healthcare (NYSE:HTA) Opportunities Fund (NYSE:THQ).

Both CEFs pay huge dividends (7.4% for THQ and over 10% for THW) while trading at discounts to their portfolios’ market value (6.5% for THQ and 7.7% for THW). Those discounts alone make them attractive, as Tekla’s funds often trade at premiums due to management’s strong past performance.

You could also consider these two funds a kind of second chance to buy Gilead—both hold the stock, and their discounts mean you can effectively buy Gilead at 6.5% or 7.7% off.

And here’s another signal that now may be the time to buy in: since their inception, both funds have been beating IBB, yet they’ve trailed the index fund year to date, though not by much.

Tekla Picks (Temporarily) Lag the Benchmark

THW-THQ IBB Total Returns
THW-THQ IBB Total Returns

The reason? Fear. CEF investors are very conservative by nature, so it’s unsurprising that many are shying away from THQ and THW during a panic—even if, ironically, these funds’ holdings are now more important to the economy than any other industry in the world.

And with high-powered scientific expertise helping these funds choose winners and dodge losers—as they’ve been doing for years—they’re worth a look. While you wait for them to regain their lead over IBB (and rise further), you’ll be collecting their attractive 7.4%+ dividends, paid monthly, no less.

The bottom line? Whether you’re relying on your portfolio for income or not, having medical pros steer your pharma holdings is a good way to profit from the sector’s growth as we move through the current crisis and into the coming recovery.

Your “Second Chance” to Buy This Rebound (With 8.4% Dividends!)

CEFs’ appeal isn’t just limited to pharma, of course. As I write this, there are some 500 CEFs in all, and they yield around 7%, on average!

They come from just about any corner of the market you can think of: there are CEFs that own bonds, S&P 500 stocks, tech stocks and even preferred shares and REITs.

Best of all, many of these proven income plays are cheap now. So if there’s a sector or investment you’ve wanted to get into but missed out on in this rally, these funds are a godsend—they give you a way to buy in at a discount, while giving you most of your return in safe dividend cash!

Consider my 4 favorite CEFs now. They pay a reliable 8.4% average dividend and form a standalone portfolio in their own right, giving you exposure to large cap US stocks, steady utilities and infrastructure names, bonds, the biggest tech plays (including Alphabet (NASDAQ:GOOGL) and Microsoft (NASDAQ:MSFT)) and, yes, pharma stocks, too.

Except instead of settling for the lame 2% dividends most investors have to scrape by on, you’ll be collecting a life-changing 8.4% cash stream! And get this: these funds are so cheap now that I’m calling for 20%+ price upside in the next 12 months—bull market or bear.

Disclosure: Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks/funds across the U.S. markets. Click here to learn how to profit from their strategies in the latest report, "7 Great Dividend Growth Stocks for a Secure Retirement."

Forget Gilead, These 2 Pharma Dividends Pay Up To 10%
 

Related Articles

Forget Gilead, These 2 Pharma Dividends Pay Up To 10%

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email